PHILADELPHIA, PA — Cabaletta Bio, Inc. (Nasdaq: CABA), a trailblazer in engineered T cell therapies for autoimmune diseases, announced its participation in the H.C. Wainwright 2nd Annual BioConnect Investor Conference. The event is scheduled for Monday, May 20, 2024, at 9:30 a.m. ET at NASDAQ in New York, NY.
This engagement will feature a fireside chat, broadening the discourse around innovative treatments for autoimmunity. A live webcast of this presentation will be accessible on Cabaletta Bio’s website, with replays available for 30 days post-event.
Cabaletta Bio leverages its proprietary CABA™ platform to develop treatments that aim for a possibly curative impact on autoimmune diseases. Their leading product candidate, CABA-201, along with other clinical-stage candidates, signifies the company’s commitment to addressing complex autoimmunities through advanced therapeutic strategies. Cabaletta Bio’s pioneering work is grounded in Philadelphia, PA, where it continues to push the boundaries of medical science.
For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News and MSN.